Developing a core outcome-domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome-domains

1	Kaiser	Ulrike	Psychology	Comprehensive Pain Center, VAPAIN University Hospital Carl Gustav Steering Carus, Technical University committee Dresden, Germany
2	Kopkow	Christian	Physiotherapy/ Public health	Department of Applied Health VAPAIN Sciences, University of Applied Steering Sciences, Bochum, Germany committee
3	Deckert	Stefanie	Public health/ Methodology	Center for Evidence-Based VAPAIN Healthcare, Hospital and Steering Medical faculty Carl Gustav committee Carus, Technical University Dresden, Germany
4	Neustadt	Katrin	Psychology	Comprehensive Pain Center, VAPAIN University Hospital Carl Gustav Steering Carus, Technical University committee Dresden, Germany
5	Jacobi	Lena	Public health/ Methodology	Center for Evidence-Based VAPAIN Healthcare, Hospital and Steering Medical faculty Carl Gustav committee Carus, Technical University Dresden, Germany
6	Cameron	Paul	Physiotherapy	Queen Margaret Hospital, VAPAIN Panel Dunfermline, Fife, Scotland, UK
7	De Angelis	Valerio	Patient representative	Patient representative, Italy VAPAIN Panel
8	Apfelbacher	Christian	Public health/ Methodology	Medical Sociology, Institute of VAPAIN Panel Epidemiology and Preventive Medicine, University of Regensburg, Germany
9	Arnold	Bernhard	Medicine	Amper Kliniken Dachau, VAPAIN Panel Germany
10	Birch	Judy	Patient representative	Patient representative; Pelvic VAPAIN Panel Pain Support Network, UK
11	Bjarnegård	Anna	Physiotherapy	Swedish Association of VAPAIN Panel Physiotherapists, Sweden

12	Christiansen Sandra	Psychology	Pain Medicine and Pain Psychology, University Medical Hospital Hamburg-Eppendorf (UKE), Center for Anesthesiology and Intensive Care Medicine, Department of Anesthesiology, Hamburg, Germany	VAPAIN Panel
13	Williams Amanda C de C	Psychology	Research Department of Clinical, Educational & Health Psychology, University College London, UK	VAPAIN Panel
14	Gossrau Gudrun	Medicine	Comprehensive Pain Center, University Hospital Carl Gustav Carus, Technical University Dresden, Germany	VAPAIN Panel
15	Heinks Andrea	Physiotherapy	German Federation of Physiotherapy, Germany	VAPAIN Panel
16	Hüppe Michael	Psychology	Department of Anesthesiology Lübeck University Medical School Lübeck, Germany	VAPAIN Panel
17	Kiers Henri	Physiotherapy	University of Applied Sciences Utrecht, The Netherlands	VAPAIN Panel
18	Kleinert Ursula	Patient representative	German pain league, Germany	VAPAIN Panel
19	Martelletti Paolo	Medicine	Sapienza University of Rome, Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, Sant'Andrea Hospital, Rome, Italy	VAPAIN Panel
20	McCracken Lance	Psychology	Psychology Department, Health Psychology Section, King's College London, UK	VAPAIN Panel
21	de Meij Nelleke	Medicine	Research and Quality Assessment; Anesthesiology and pain medicine; University Pain Center Maastricht, Maastricht UMC+, The Netherlands	VAPAIN Panel
22	Nagel Bernd	Medicine	Day Care Unit, DRK Pain Center Mainz, Germany	VAPAIN Panel

23	Nijs	Jo	Physiotherapy	Vrije Universiteit Brussel, VAPAIN Panel Department of Physiotherapy, Human Physiology & Anatomy, Faculty of physical education & physiotherapy, Brussels, Belgium
24	Norda	Heike	Patient representative	Patient federation VAPAIN Panel "SchmerzLOS e.V.", Germany
25	Singh	Jasvinder A.	Public health/ Methodology	University of Alabama at VAPAIN Panel Birmingham and Birmingham, Birmingham Veterans Affairs Medical Center, AL, USA
26	Spengler	Ellen	Patient representative	Patient representative, VAPAIN Panel Germany
27	Terwee	Caroline	Public health/ Methodology	VU University Medical Center; VAPAIN Panel Department of Epidemiology and Biostatistics, Amsterdam Public Health research institute, Amsterdam, The Netherlands
28	Peter	Tugwell	Public health/ Methodology	Faculty of Medicine, VAPAIN Panel Department of Epidemiology & Community Medicine, Ottawa, Canada
29	Vlaeyen	Johan W.S.	Psychology	University of Leuven, Research VAPAIN Panel Group Health Psychology, Leuven, Belgium
31	Neugebauer	Edmund	Public health/ Methodology	Brandenburg Medical school Neuruppin and Witten- Herdecke University, Germany
32	Sabatowski	Rainer	Medicine	Comprehensive Pain Center, VAPAIN University Hospital Carl Gustav Steering Carus, Technical University committee Dresden, Germany
33	Schmitt	Jochen	Public health/ Methodology	Center for Evidence-Based VAPAIN Panel Healthcare, Hospital and Medical faculty Carl Gustav Carus, Technical University Dresden, Germany

Correspondence:

Dr. rer. nat. Dipl.-Psych. Ulrike Kaiser
Comprehensive Pain Center
University Hospital “Carl Gustav Carus”, Technical University Dresden
Fetscherstraße 74
01307 Dresden, Germany
Phone: +49 (0) 351 458 4547
Fax: +49 (0) 351 458 6391
ulrike.kaiser.usc-tkl@uniklinikum-dresden.de

Funding Sources: The study is funded by the German Federal Ministry of Education and Research (BMBF 01GY1326).

Abstract

Interdisciplinary multimodal pain therapy (IMPT) is a biopsychosocial treatment approach for patients with chronic pain that comprises at least psychological and physiotherapeutic interventions. Core Outcome Sets (COSs) are currently developed in different medical fields to standardize and improve the selection of outcome-domains, and measurement instruments in clinical trials, to make trial results meaningful, to pool trial results, and to allow indirect comparison between interventions. The objective of this study was to develop a COS of patient-relevant outcome-domains for chronic pain in IMPT clinical trials.

An international, multi-professional panel (patient representatives (n=5), physicians specialized in pain medicine (n=5), physiotherapists (n=5), clinical psychologists (n=5), and methodological researchers (n=5)) was recruited for a 3-stage consensus study, which consisted of a mixed-method approach comprising an exploratory systematic review, a preparing online survey to identify important outcome-domains, a face-to-face consensus meeting to agree on COS domains, and a second online survey (Delphi) establishing agreement on definitions for the domains included.

The panel agreed on the following eight domains to be included into the COS for IMPT: pain intensity, pain frequency, physical activity, emotional wellbeing, satisfaction with social roles and activities, productivity (paid and unpaid, at home and at work, inclusive presentism and absenteeism), health-related quality of life, and patient's perception of treatment goal achievement.

The complexity of chronic pain in a biopsychosocial context is reflected in the current recommendation, and includes physical, mental and social outcomes. In a subsequent step measurement instruments will be identified via systematic reviews.

Keywords: Chronic pain, interdisciplinary multimodal pain therapy, core outcome set, consensus process, outcome domains

Introduction

Interdisciplinary multimodal pain therapy (IMPT) is a biopsychosocial approach for patients with chronic pain^{12,13,14,24,26,27,30}, meanwhile recognized internationally^{15,32}. IMPT consists, minimally, of psychological and physiotherapeutic interventions, aiming to increase patients' physical and psychological function and activity towards defined goals and improving adjustment to pain. In some countries additionally active participation of physicians is mandatory²¹. Existing diversity of outcomes⁸, and methodologies for outcome assessment²², hampers comparison of clinical trials (including outcome-reporting bias⁴²), and knowledge translation⁸. The development of a core outcome set (COS) would address this situation^{8,42}. A COS is defined as a minimum set of relevant outcome-domains, and reliable measurement instruments within those domains, that are required to be measured and reported in all clinical trials²⁸.

Developing COSs involves a multi-method approach consisting of systematic reviews and consensus processes^{2,34}. The application of COSs should not be restricted to clinical trials only. Its application in routine care supports generation of evidence from observational studies and clinical registries as well⁶. It seems reasonable to create a COS which can be used across all study designs both in efficacy/effectiveness studies, and routine daily record keeping. A COS for daily record keeping refers to standardized documentation, with a minimal amount of outcome-domains, monitoring the patient's status throughout routine care and can be simultaneously used for quality management purposes.

The involvement of key stakeholders is highly recommended by the HOME roadmap (*Harmonizing outcome Measurement in Eczema*) for COS development³⁴, with methodological approaches such as the use of expert panels, and considered essential for acceptance of a COS by future users^{25,31}. For IMPT, relevant stakeholders consist of at least all key health professions involved, patient representatives, physicians specialized in pain medicine, physiotherapists, clinical psychologists, and methodological researchers.

The discussion about COS in the therapy of chronic pain has been established by IMMPACT¹⁷, and developed by other initiatives recently²⁰. Nevertheless heterogeneity of outcome assessment is still present⁸.

Applying COS in IMPT requires a multidimensional approach, consisting of biological, psychological, and social aspects thus mirroring therapy aims. IMMPACT^{37,38}, as the most acquainted initiative, defined COS for all forms of chronic pain therapies, but focused mainly on medication in clinical trials³⁶ and not on comprehensive therapy approaches such as IMPT.

Inclusion of patients in COS development is recommended to provide a patient perspective on relevant outcome-domains². Patient preferred domains³⁸ do not consistently match with previous COS recommendations³⁷, and this gap remains to be filled.

Therefore, two main reasons exist to develop a COS in IMPT¹⁹:

1. IMPT patients have protracted, and ongoing, pain. Pain interferes with most life domains, thus changes in biopsychosocial aspects need to be considered when assessing therapies.
2. The primary aim of IMPT is not reduction of pain in the first instance, but focusing on general improvements in physical, psychological, and social aspects according to patients' experience.

“Validation and Application of a patient-relevant core set of outcome-domains to assess multimodal PAIN therapy” (VAPAIN)¹⁹ targets on developing a consensus-based COS of patient-relevant outcome-domains for chronic pain in IMPT for efficacy/effectiveness studies (ES) and daily record keeping (DRK).

Methods

Protocol, registration and ethical approval

Reporting of this study follows the Core Outcome Set-Standards for Reporting (COS-STAR)²³ guidelines. The study protocol was published *a priori*¹⁹, along with the registration of VAPAIN in the *Core Outcome Measures in Effectiveness Trials* (COMET) database⁷. Ethical approval was obtained from the Ethical Committee of the Medical Faculty of the Technical University Dresden (EK 105032015).

Organization of the VAPAIN consensus process

Three groups with different functions were involved into project conduction: the VAPAIN steering committee (UK, SD, CK, KN, LJ, RS), the VAPAIN advisory board and the VAPAIN panel.

The steering committee was responsible for conducting all systematic literature reviews, the planning, conducting and preparing of all results to be provided to the VAPAIN panel for the consensus process on domains and definitions. The steering committee was not involved into content related activities. The VAPAIN advisory board consisted of clinicians, methodological researchers, and patient representatives and was responsible to observe and advice the project realization to ensure high quality. It was independent in person and action from all the other VAPAIN groups. The VAPAIN panel was invited to discuss and vote, to align on outcome domains for IMPT.

Eligibility criteria: Selection of the VAPAIN panel

Eligibility of VAPAIN panel members was defined as being representative of a relevant stakeholder group of IMPT in clinical research and/or daily practice: patients, physicians specialized in pain medicine, physiotherapists, clinical psychologists, and methodological researchers. VAPAIN panel members were experienced in their fields (clinicians were supposed to be at least acquainted with IMPT and its therapeutic components), were nominated by international organizations, and scientific associations related to pain and/or chronic pain to control for selection bias, and were able to take part in the full process.

Project schedule

We conducted a 3-stage consensus study, using a mixed-methods approach (*fig. 1*) consisting of an initial systematic review⁸, preparing online survey to identify outcome-domains (initial outcome-domains; *step 1, 1.1-1.2*; April-June 2014), a 2-day face-to-face consensus meeting to discuss and agree on COS domains (November 2014, *step 1, 1.3*), and a further online survey (Delphi) to establish agreement of domain definitions included in the COS (March-October 2015, *step 2, 2.1-2.3*). All stages were supervised by a multi-professional advisory board (including patient representatives) for quality assurance throughout.

Information sources

-Systematic review: First (see *Fig. 1*), a systematic review was conducted to prepare a list of the most reported outcome-domains for chronic pain in the context of IMPT⁸. More than 140 different outcome-domains with different abstraction levels and conceptual quality were identified. It was infeasible to provide all of these to the VAPAIN panel for consideration; therefore only outcomes found in at least 10% of included studies were selected. Thus, a total of 19 outcome-domains were included (*Table 1*). The Patient-Reported Outcomes

Measurement Information System (*PROMIS*)^{3,16} was assumed the theoretical framework to classify identified outcome-domains, capturing the biopsychosocial model of chronic pain and IMPT. Domains were organized into physical, psychological, and social health areas as aspects of health condition that need to be measured to appropriately assess the effects of a health intervention and comprises domains as components of core areas to be a specification of an aspect of health².

- **online survey domains:** To prevent selection bias, the VAPAIN panel was asked during round 1.1 (Fig. 1) to add relevant outcome-domains not found among the 19 domains pre-selected. The pre-selected domains were provided with definitions according to literature. The outcome-domains indicated by the VAPAIN panel were forwarded into the domain selection without restriction. No other a priori criteria were applied at this point.

- **face-to-face meeting:** Prior to the meeting, all VAPAIN panel members received a booklet with pertinent information regarding the development of COS, VAPAIN, and additional publications for information about domains. Presentations provided information about IMPT, COS initiatives, HOME roadmap of COS development, the VAPAIN study, and the results from the online survey.

To avoid intimidation of the patient representatives, several strategies were used to promote their participation. Prior to the meeting patients had been invited to a briefing, at which the organizers explained the rationale of the meeting, definitions, and their role as participants. The small group discussions were held in peer groups so that patients had the opportunity to identify themselves as a group, and discussion in the large group started with the results of the patient peer group. During the large group discussion the facilitator started with patients' opinions, and supported different perspectives when they were presented by patient representatives. If the VAPAIN panel was not able to agree to a construct, patients' perspectives determined the final panel decision.

More details regarding the meeting can be found at VAPAIN Website³⁸.

- **online survey domain definitions:** For all of the consented domains officially published and consented definitions if available were presented to the VAPAIN panel. Supplementary notes from the meeting were provided for a consistent awareness of the previous discussion (available online as supplemental digital content at <http://links.lww.com/PAIN/A519>).

Consensus process

-Online Survey “domains for ES and DRK” (step 1, round 1.1-1.2)-

The aim of the first online survey (*round 1.1-1.2*) was to prepare preliminary multi-professional and international agreement on a specific COS domains for efficacy/effectiveness studies, and daily record keeping in IMPT.

Participants' characteristics of the VAPAIN panel were obtained.

The initial systematic-review-derived outcome-domains were provided to the VAPAIN panel during **round 1 of online survey (1.1)** via **Delphi manager** software (supported by the COMET initiative, <http://www.comet-initiative.org/delphimanager/>). VAPAIN panel members were asked to rate the importance of proposed domains regarding a) efficacy/effectiveness studies and b) daily record keeping. Furthermore, all members specified minimum and maximum number of outcome-domains to be included into the COS for both trial and daily use.

During **round 2 (1.2)**, VAPAIN panel members received feedback on their own ratings as well as those from the entire VAPAIN panel in a separate document attached to the invitation email. In different colors their personal and the vote of the group were highlighted for each question. New outcome-domains added by VAPAIN panel members in *round 1* were included into *round 2* for rating by all VAPAIN panel members. Participants were informed about the minimum and maximum number of domains (median of positive voting) to be included in the COS, according to results from *round 1*. VAPAIN panel members then indicated outcome-domains to be included in each COS according to the minimum/maximum number stated.

Outcome scoring: The importance of outcome-domains was rated on a scale from 1 to 9, with 1-3 “*not important*”, 4-6 “*important but not critical*”, and 7-9 “*critical*”¹⁸. VAPAIN panel members were allowed to choose “*unable to score*”. The median was used to summarize results for each domain.

-Presence meeting “domains for ES and DRK” (step 2, 1.3)-

The aim of the meeting was to achieve final consensus of outcome-domains to be included in the COS. A 2-day consensus meeting was held in Dresden, Germany from November 27 to 28, 2014. Two facilitators (EN and UK) guided discussions following group discussion methods^{18,43}.

The meeting focused primarily on the COS domains for efficacy/effectiveness studies. Participants were separated into stakeholder groups, each supported by one methodological expert. The groups were advised to rate candidate domains as “*included*”, “*unclear*”, or “*excluded*” if considered not important for the COS. Results were presented to the complete panel. Starting patient-centered with the results from the patients’ group, all domains labeled “*to be included*” were discussed by the entire group, followed by the “*unclear*” domains.

Panel members were advised to discuss the reasons for inclusion or exclusion of initial domains. They were encouraged to either drop or combine domains or get more abstract levels to feel as secure as possible about comprehensiveness of the domain for patients with chronic pain. The final consensus of the panel, by majority, was required in order to include the specific domain into the COS.

Voting was anonymous and analyzed simultaneously by VAPAIN steering committee members to enable immediate feedback for the discussion. The VAPAIN panel decided to vote anonymously and weighting was therefore not considered necessary by the entire group and steering committee.

Definition of consensus: The panel decided to use $\geq 70\%$ of VAPAIN panel members voting yes for a domain, to include a domain into the COS². In cases where the 70% criterion was not achieved, domains were discussed again and another vote was taken.

After the COS domains for efficacy/effectiveness studies were agreed, potential outcome-domains for the COS daily record keeping were discussed.

-Online Survey “definition of domains” (step 2, round 2.1-2.3)-

The aim of this online survey was to achieve final consensus on definition of recommended outcome-domains, which was felt to be essential for subsequent systematic reviews to identify the most relevant measurement instruments¹⁹. The iterative web-based survey consisted of three Delphi rounds, and an intermediate round was conducted via SurveyMonkey³⁵ inviting the same VAPAIN panel members. They were asked to comment on, and rate, the proposed definitions in three rounds (2.1-2.3). For *emotional wellbeing* (conceptual divergences within panel members) and *patient’s perception of treatment goal achievement* (divergences of wording) an additional round was needed (fig. 1 step 2, 2.2-1).

Outcome scoring: Panel members were asked to rate according to 4 possible categories: “I agree”, “The proposed definition needs modification”, “I disagree”, or “unable to score”. For each domain frequencies were estimated for all specific categories.

Definition of consensus: The same rule as described above (*step 2*, face-to-face meeting).

Debating and voting

Discussion was led by two facilitators (EN, UK), aiming that everyone’s comment and opinion was heard and sufficiently acknowledged by the entire VAPAIN panel. The facilitators encouraged maximum integration of outcomes of group work (applying nominal group technique), with visual records displayed to aid the process. Starting with the outcome of the patient representatives’ discussion, each domain was discussed in detail by the entire panel, proceeding to a vote once participants felt that all issues related to the particular domain had been comprehensively discussed, and facilitators assured that all panel members felt heard and their views acknowledged. In the case of an ambiguous decision, patient representatives were asked for their views.

Results

Protocol deviations

During the online survey *step 1* it became obvious that the different professions with different backgrounds needed more space for detailed deliberation to enable a final agreement of COS domains by the entire VAPAIN panel. Therefore the last round of *step 1* online survey was skipped and the VAPAIN panel members were invited to the face-to-face-meeting originally planned to decide about measurement instruments. After completing agreement on outcome-domains a Delphi approach was conducted for defining the recommended domains (*fig.1 step 2, 2.1-2.3*) in a supplemental, originally not planned step.

VAPAIN panel members

A total of 25 individuals were recruited (5 of each patient representatives, physicians, physiotherapists, clinical psychologists, and methodological researchers) and addressed as representatives of their organizations (*Table 2*). Characteristics are presented in *Table 3*. With reference to experience of scientific processes among patient representatives, four out of five

were either long-term leading or active members in self-help organizations, had organized meetings, or had collaborated in scientific committees before.

Outcomes

Online Survey “domains for ES and DRK” (step 1)

Response rates for *round 1* and *round 2* were 100% (n=25) and 88% (n=22), respectively. VAPAIN panel members decided that the COS domains for efficacy/effectiveness studies should contain a minimum of 4 (in order to be comprehensive enough), and a maximum of 9 domains (due to concern about respondent burden). For daily record keeping a minimum of 3 and a maximum of 6 domains were considered appropriate. In total, 38 outcome-domains were provided and grouped into the 6 core areas of *general quality of life, health related quality of life, sickness impact, mental health, social health* and, *physical health*.

A wide range of ratings was observed during both rounds for most of the domains, with a median of ≥ 7 (see *Table 1*) for efficacy/effectiveness studies as well as daily record keeping, indicating very different perspectives among the VAPAIN panel members on what should be measured.

Presence meeting „domains for ES and DRK“(step 2)

COS for efficacy/effectiveness studies (ES) in IMPT

- Results of the small group voting

In summary, patient representatives rated 14 outcome-domains as relevant for a COS for efficacy/effectiveness studies in IMPT. There were large differences between stakeholder groups, most notable between patient representatives and clinical psychologists; 50% (n=7) of the domains voted by the patients as “critical”, were voted for exclusion by the clinical psychologists. This observation mainly referred to psychological issues, which patient representatives felt to be of high importance, whereby clinical psychologists defined most of those domains to be rather process variables of IMPT than outcomes. For *pain intensity* and *pain frequency* there was substantial disagreement due to some VAPAIN panel members arguing that both outcome-domains should not be part of the COS in chronic pain since there

is not much change during therapy. The opposite opinion was to include both domains because the treatment approach still targets on pain. The sole agreement throughout all groups was observed for *health-related quality of life*.

- Results from the plenary voting

The following eight domains were voted for inclusion by at least 70% of all meeting VAPAIN panel members to be included for efficacy/effectiveness studies: 1) *pain intensity*, 2) *pain frequency*, 3) *physical activity*, 4) *emotional wellbeing*, 5) *satisfaction with social roles and activities*, 6) *productivity (paid and unpaid, at home and at work, including presentism and absenteeism)*, 7) *health-related quality of life*, 8) and *patient's perception of treatment goal achievement* (see Table 4). Only *pain intensity*, *pain frequency*, and *health related quality of life* were adopted from the previous online survey, the other domains emerged from debating preselected and provided domains. A short summary of minutes from the face-to-face meeting is available via online supplement (available online as supplemental digital content at <http://links.lww.com/PAIN/A519>).

By reference to OMERACT recommendations², the VAPAIN panel recommended *withdrawal from therapy/side effects* as critical domains.

COS for daily record keeping (DRK) in IMPT

The VAPAIN panel discussed the importance of daily record keeping COSs, referring particularly to the purposes of a COS for daily records, and different national requirements. No agreement was achieved, and the VAPAIN panel decided to primarily focus on the COS in efficacy/effectiveness studies, adjourning the debate about a COS for daily record keeping.

Online Surveys “definitions of domains” (step 2, 2.1-2.3)

During online survey round 2.1-2.3 (fig. 1, Table 5), VAPAIN panel members were provided with possible definitions (step 2, presence meeting). For *emotional wellbeing*, VAPAIN panel members received three possible definitions^{9,10,40}; the wording of *patient's perception of treatment goal achievement* was discussed at length. Response rate of the four rounds (three to discuss, and vote, for domain definitions and an additional round to clarify the definitions of *emotional wellbeing* and *patient's perception of treatment goal achievement*) ranged from

100% (2.1, 2.3) to 80% (2.2, 2.2-1). Final results are presented in *Table 5*. For all outcome-domain definitions but one (*pain frequency*) a consensus was achieved.

Discussion

Following an iterative process of evidence synthesis and international multi-stakeholder discussion among patient representatives, physicians specialized in pain medicine, physiotherapists, clinical psychologists, and methodological researchers, eight core outcome-domains were consented to be used in every efficacy/effectiveness study in interdisciplinary multimodal pain therapy.

All outcome-domains are provided with a definition agreed by the VAPAIN panel, except *pain frequency*. During the face-to-face-discussion, several earlier mooted outcome-domains were subsumed or changed into other outcome-domains. The VAPAIN recommendation comprises three frequently reported (*pain intensity*, *pain frequency* and *health related quality of life*)⁸, and five outcomes less commonly used. The balance of physical outcomes (*pain intensity*, *pain frequency*, and *physical activity*), psychological outcomes (*emotional wellbeing*), social outcomes (*satisfaction with social roles and social activities*, *productivity*) and overarching outcomes (*health related quality of life*, *patient's perception of treatment goal achievement*) satisfies the requirement for biopsychosocial applicability. There was discussion of the possible need in addition for outcome-domains specific to conditions such as low back pain, headache or neuropathic pain.

A core set for daily record keeping was not achieved due to dis-agreement amongst VAPAIN panel members on the purpose, and aim, in IMPT, further complicated by different national requirements, and resources. Nevertheless the VAPAIN panel did not reject the importance of a COS for daily record keeping.

Since the perspective of IMPT is multidimensional, the interests and perspectives at the beginning of the process were predictably heterogeneous. Legitimate differences of opinion were due to the multidisciplinary, personal and national backgrounds, and only by open face-to-face-discussion was it possible to achieve consensus on outcome-domains, as well as on umbrella terms and handling of subgroup specific views.

The use of consistent outcome-domains in trials would be an important contribution to assist in understanding the common problem of differing results between efficacy and effectiveness studies. Therefore, the uniform inclusion of the VAPAIN COS (including *withdrawal from therapy/side effects*) is recommended for both effectiveness and efficacy studies.

Efficacy/effectiveness cannot be assumed but needs to be proven by relevant (also including patient-relevant) criteria normally defined a priori and derived from the needs of a specific patient population. Treatment approaches can thereby be estimated to be beneficial or not, and compared to other interventions in order to estimate superiority for a specific health condition. Therefore it is necessary to start from therapy aims (as operationalized in outcome parameter and based on patients' needs) to identify effectiveness of interventions. Following this idea, outcome domains need to refer to what is important to patients undergoing the intervention, and need to be multidimensional in the case of chronic pain. The relevance of therapeutic aims in the development of COS has not been adequately discussed to date and this could lead to insufficient coverage of a COS for a specific target population. This might be an important issue particularly in future applications of COS.

VAPAIN has started with therapeutic aims of IMPT, providing the basis for further investigation of which kind of interventions or combination of interventions (including dose, and content) best serve patients with chronic pain. This might lead to future adaptations of the composition of interventions of IMPT, enlighten the superiority of one intervention above others (e.g. specific physiotherapeutic or psychological interventions) by meta-analyses or even result in adaptations of treatment models. The provision of specific designed multicomponent treatments for specific subgroups of patients with chronic pain in public health delivery, including restricted applications of IMPT for patient with lower levels of chronicity, would be a potential and resource-saving consequence.

For the consideration of representativeness and generalizability of the findings, several aspects need to be addressed. The sample size in this project refers to the amount of specialists of IMPT who were willing to participate as well as to financial budget. Even though the eligibility criteria demanded clinicians experienced in the field of IMPT, it was not possible to ensure such an expertise internationally, so it was accepted when experienced clinicians were acquainted to IMPT, and experienced in the field of comprehensive pain therapy, even if their work environment did not match the applied definition of IMPT completely. Nomination by scientific organizations was addressed to ensure a broad variety of international members, but many of the nominated individuals came from Germany where IMPT is frequently applied. Another limitation is the design of the first step; whereby systematic review identified outcome-domains were pre-structured before providing to VAPAIN panel voting. This was necessary because of the excessive number of identified

outcome-domains in effectiveness studies investigating IMPT. The opportunity to add additional outcome-domains was considered valid and important.

Outcomes need to be important to patients, clinicians, and other key decision makers^{25,31}. Patient perspective has often been insufficiently considered when developing COSs, or introduced only at a late stage. In VAPAIN, patient representatives were involved from the outset. Their opinions were invited first. The inclusion of patients legitimized the process and influenced the discussion at every point, such as the meaning of psychological factors and their heterogeneous distribution, or the difference between *physical function* and *activity*. Even though the participating patient representatives have been identified by public self-help organizations, the question remains if their opinion reflects the experience of the majority of patients with chronic pain. A potential selection bias could arise from the social background, financial resources and educational level of patients willing to participate in scientific processes. According to previous investigations on patients with chronic pain in a German sample the VAPAIN domains have essentially been validated²⁷. Another survey in patients with chronic pain reveals considerable overlaps with the VAPAIN recommendation (*emotional wellbeing, physical activities, several social areas*), especially emphasizing the social component (8 out of 19 domains)³⁸.

Compared to other recommendations (e.g. IMMPACT^{37,38}, on low back pain⁵) VAPAIN has produced some different results. VAPAIN has primarily focused on a specific, per se, heterogeneous sample (chronic pain) for a specific treatment approach (IMPT) in efficacy/effectiveness studies, considering chronic pain as a bio-psycho-social phenomenon, referring to PROMIS framework^{3,16} as a relevant framework capturing bio-psycho-social perspectives on health care. The different scopes of other outcome initiatives particularly regarded to drug trials³⁷, or a specific target population (non-specific low back pain⁵). Both initiatives focus on functional aspects (*physical*), and *pain intensity*^{5,37}, added by *emotional functioning, participants' ratings of global improvement, symptoms and side effects* as well as *participants dispositions*³⁷, or *HrQL* and *number of death*⁵. Domains such as productivity or work ability, important domains according to the public health perspective, and ensuring patients' social participation and financial security, were not considered³⁷ or excluded⁵, while domains concerning social participation have not been recommended. Regarding the psychological health area VAPAIN recommended *emotional wellbeing* instead of *emotional functioning*³⁷. Despite the fact, that *emotional functioning* mainly refers to basic abilities such as awareness, expression and regulation of emotions and therefore is not sufficiently

operationalized by domains such as depression or anxiety³⁷, patient representatives of the VAPAIN panel reported that it is more the emotional burden of chronic pain, including anger, grief, distress, anxiety and depressiveness, they want to be changed by IMPT. Because of the heterogeneity of distressing emotions an overarching domain became necessary to capture most of the emotional changes in patients attending IMPT, which was chosen by indicating *emotional wellbeing* as an outcome domain. However, according to a previous survey in patients with chronic pain³⁸, especially the social as well as the psychological health area were indicated as of highest importance. Including the perspective of patients in establishing core outcome sets means to consider their needs of restoration ability to get back to a personally satisfying life, which always includes biological, at least in terms of functional, psychological and eventually social dimensions.

VAPAIN has followed established guidelines for COS development to enhance transparency of process and results. Further, starting from therapy aims, and involving patient representatives fully in discussion throughout the consensus process of VAPAIN, may have contributed to the differences in outcome recommendations compared to other initiatives^{5,37}. The experience of the stakeholders in comprehensive treatment approaches in chronic pain and the steady awareness of a bio-psycho-social perspective have led to the suggestion of five completely new outcome domains. Above all, a consensus in this subject would not have been accomplished by online surveys, where perspectives cannot be negotiated.

Other issues concern the importance of additional domains, and the associated need to classify outcome-domains in relation to their relevance to specific chronic pain conditions. Since the population of patients with chronic pain in IMPT is frequently heterogeneous, the idea of finding an overarching domain, which covers most of the heterogeneous sample, and is still sensitive enough to measure change, is particularly challenging. This emphasizes the importance of a continuing validation process, after identification of measurement instruments, to investigate overlaps, and distinction of theoretical underlying constructs.

Developing a COS on domains is insufficient to ensure high quality studies in trials and routine care. The identification of reliable and valid instruments will be a critical next step. A shortlist of reliable instruments and validation studies to date, related to outcome-domains, will provide an invaluable resource to clinicians and researchers.

Acknowledgements

The study has been funded by German Ministry of Education and Research (BMBF 01GY1326).

We sincerely thank Paula Williamson (COMET) for advice and provision of *DelphiManager* software (<http://www.comet-initiative.org/delphimanager/>) and Melanie Harper and Duncan Appelbe for the technical support in conducting online survey 1.

VAPAIN was advised by a multi-professional advisory board regularly. Members of the AdBoard were Josef Norda† and Anja Lehmann (patient research partners), Edmund Neugebauer (public health), Michael Pfingsten (psychology), Winfried Meissner (anaesthesiology, specialized in pain medicine), Kerstin Weidner (psychosomatic medicine), Thea Koch (anaesthesiology), Uwe Ettrich (orthopedy), Birgit Konrad (physiotherapy), Heinz Reichmann (neurology), Maria Eberlein-Gonska (quality management).

The VAPAIN steering committee has prepared, edited the draft and coordinated the publication process. UK, SD, CK and KN have prepared the manuscript including tables and images, coordinated by UK. JS, RS and PC have edited the draft. EN and HW reviewed the manuscript a priori submission and resubmission and gave comment on comprehensibility, structure and content. All VAPAIN panel members reviewed the final draft and endorsed its publication. All VAPAIN panel members reviewed the final draft, provided comments and endorsed its publication.

There are no conflicts of interests regarding all authors except JAS, CA, JS and EN.

JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-

analysis. CA reports personal fees and non-financial support from Cogitando Healthcare, outside the submitted work.

JS reports grants from ALK, Novartis, Pfizer, Sanofi, outside the submitted work.

EN reports personal fees from Gruenenthal, personal fees from AstraZeneca, outside the submitted work.

UK reports grants from BMBF, during the conduct of the study.

References

1. Beaton D, Bombardier C, Escorpizo R, Zhang W, Lacaille D, Boonen A, Osborne RH, Anis AH, Strand V, Tugwell PS. Measuring Worker Productivity: Frameworks and Measures. *J Rheum* 2009;36(9):2100-9.
2. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino M-A, Conaghan PG, Bingham III CO, Brooks P, Landewé R, March L, Simon LS, Singh JA, Strand V, Tugwell P. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. *J Clin Epidemiol* 2014;67(7):745-53.
3. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M. The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap Cooperative Group During its first two years. *Med Care* 2007;45(5 Suppl 1): S3-S11.
4. Cella D. Measuring quality of life in palliative care. *Seminars in Oncology* 1995;22:73-81.
5. Chiarotto A, Deyo RA, Terwee CB, Boers M, Buchbinder R, Corbin TP, Costa LOP, Foster NE, Grotle M, Koes BW, Kovacs FM, Lin CWC, Maher CG, Pearson AM, Peul WC, Schoene ML, Turk DC, van Tulder MW, Ostelo RW. Core outcome-domains for clinical trials in non-specific low back pain. *Eur Spine J* 2015;24(6):1127-42.
6. Clarke M. Standardising outcomes for clinical trials and systematic reviews. *Trials* 2007;8:39.
7. COMET. Available at: <<http://www.comet-initiative.org/studies/search>> Accessed Dec 31, 2016.

8. Deckert S, Kaiser U, Kopkow C, Trautmann F, Sabatowski R, Schmitt J. A systematic review of the outcomes reported in multimodal pain therapy for chronic pain. *Eur J Pain* 2016;20:51–63.
9. Diener E, Larsen RJ. The Experience of Emotional Well-Being. In: M Lewis, JM Haviland, editors. *Handbook of Emotions*. New York: The Guilford Press; 1993. p. 405-15.
10. Diener E. Subjective Well-Being. *The Science of Happiness and a Proposal for a National Index*. *American Psychologist* 2000;55(1):34-43.
11. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Sinmon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005;113:9-19.
12. Engel GL. The need for a new medical model: a challenge for biomedicine. *Science* 1977; 196:129-36.
13. Feinberg SD, Gatchel RJ, Stanos S, Feinberg R, Johnson-Montieth V. Interdisciplinary Functional Restoration and Pain Programs. In: Deer TR, Leong MS, Ray AL, editors. *Treatment of Chronic Pain by Integrative Approaches*. New York: Springer; 2015. p. 169-82.
14. Fordyce WE, Fowler RS, Lehmann JF, Delateur BJ. Some implications of learning in problems of chronic pain. *J Chron Dis* 1968;21:179-90.
15. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. *American Psychologist* 2014;69(2):119-30.
16. Idzerda L, Rader T, Tugwell P, Boers M. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets. *J Rheumatol* 2014;41:986–93.
17. IMMPACT. Available at: <<http://immpact.org/>> Accessed Dec 31, 2016.
18. Jones J, Hunter D. Consensus methods for medical and health services research. *BMJ* 1995;5(311):376-80.
19. Kaiser U, Kopkow C, Deckert S, Sabatowski R, Schmitt J. Validation and application of a core set of patient-relevant outcome-domains to assess the effectiveness of

- multimodal pain therapy (VAPAIN) - a study protocol. *BMJ open* 2015;5:e008146. doi:10.1136/bmjopen-2015-008146.
20. Kaiser U, Neustadt K, Kopkow C, Schmitt J, Sabatowski R. Core Outcome Sets and multidimensional assessment tools for Harmonizing Outcome Measure in chronic pain and back pain. *Healthcare* 2016; 4, 63. doi:10.3390/healthcare4030063.
  21. Kaiser U, Treede RD, Sabatowski R. Multimodal pain therapy in chronic non-cancer pain - gold standard or need for further clarification? *Pain* 2017; 158 (10): 1853-9
  22. Kamper SJ, Apeldoorn A, Chiarotto A, Smeets RJE, Ostelo RWJG, Guzman J, van Tulder MW. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. *Cochrane Database Syst Rev* 2014; 2(9):CD000963.
  23. Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Moher D, Schmitt J, Tugwell P, Tunis S, Williamson PR. Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. *PLoS Med* 2016;13(10):e1002148.
  24. Loeser JD, Cahana A. Pain Medicine Versus Pain Management: Ethical Dilemmas Created by Contemporary Medicine and Business. *Clin J Pain* 2013;29:311–6.
  25. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Sprangers MAG, Blazeby JM. Developing core outcome sets: Methods for identifying and including patient-reported outcomes (PROs). *Trials* 2014;15:49.
  26. Mayer TG, Gatchel RJ. *Functional Restoration in Spinal Disorders: The Sports Medicine Approach*. Philadelphia: Lea & Febiger; 1988.
  27. Neustadt K, Deckert S, Kopkow C, Jacobis L, Preißler A, Stittl R, Mackenklodt P, Funke C, Seidel B, Bosse E, Nagel B, Hans R, Sabatowski R, Schmitt J, Kaiser U. [What does pain intensity mean from the patient perspective? A qualitative study on the patient perspective of pain intensity as an outcome parameter in treatment evaluation and on the interpretability of pain intensity measurement. *Schmerz* 2017; DOI 10.1007/s00482-017-0234-x
  28. NG LKY (ed.). *New Approaches to treatment of Chronic Pain: A Review of Multidisciplinary Pain Clinics*. Rockville: NIDA Research Monograph 36; 1981.
  29. Prinsen C A, Vohra S, Rose MR. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a 'core outcome set'. *Trials* 2014;15(1):247.

30. PROMIS framework. Available at:
<<http://www.nihpromis.org/measures/domainframework1>> Accessed Dec 31, 2016.
31. Sabatowski R, Schäfer D, Kasper SM, Brunsch H, Radbruch L. Pain Treatment: A Historical Overview. *Curr Pharm Des* 2004;10:701-16.
32. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. *Arthrit Care Res* 2010;62:640–6.
33. Schatman ME. Interdisciplinary chronic pain management: Perspectives on history, current status, and future viability. In: Fishman SM, Ballantyne JC, Rathmell JP, editors. *Bonica's Management of Pain*. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2010. p. 1523–32.
34. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues, In: Spilker B, editor. *Quality of Life and Pharmacoeconomics in Clinical Trials*. Philadelphia: Lippincott-Raven Publishers; 1996. p.11-23.
35. Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, Chalmers J, Williams HC. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: A methodological framework to develop core sets of outcome measurements in dermatology. *J Investig Dermatol* 2015;135:24–30.
36. SURVEYMONKEY. Available at: <<https://de.surveymonkey.com/>> Accessed Dec 31, 2016.
37. Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, Clauw DJ, Gignac MA, Markman JD, Williams DA, Bujanover S, Burke LB, Carr DB, Choy EH, Conaghan PG, Cowan P, Farrar JT, Freeman R, Gewandter J, Gilron I, Goli V, Gover TD, Haddox JD, Kerns RD, Kopecky EA, Lee DA, Malamut R, Mease P, Rappaport BA, Simon LS, Singh JA, Smith SM, Strand V, Tugwell P, Vanhove GF, Veasley C, Walco GA, Wasan AD Witter J. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. *PAIN* 2016; 157(9):1836-50.
38. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, Mc Cormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome-domains for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2003;106(3):337-45.

39. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, Cleeland CS, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA. Identifying important outcome-domains for chronic pain clinical trials: an IMMPACT survey of people with pain. *Pain* 2008;137:276-85.
40. VAPAIN Available at: <https://www.uniklinikum-dresden.de/de/das-klinikum/universitaetscentren/usc/studien-projekte/vapain/vapain_eng> Accessed Dec 31, 2016.
41. White M, Dolan P. Accounting for the richness of our daily activities. *Psychological Science* 2009;20(8):1000-8.
42. WHO. Available at: <<http://www.who.int/mediacentre/factsheets/fs385/en/>>. Accessed Dec 31, 2016.
43. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, Tugwell P. Developing core outcome sets for clinical trials: issues to consider. *Trials* 2012;13:132.
44. Young KS, Wood JT, Phillips GM, Pedersen DJ. Group discussion: A practical guide to participation and leadership. Long Grove, Illinois: Waveland Press; 2008.

Legends of figures and tables

Figure 1 Procedure and Regulations of Consensus of VAPAIN

Table 1 Initial outcome-domains derived from systematic literature review and VAPAIN panel suggestion with voting results from round 2 of online survey (step 1, 1.2)

Table 2 Nominating organizations and professions of the VAPAIN panel members

Table 3 Sample size description of the VAPAIN panel members

Table 4 Final voting on outcome-domains for IMPT, face-to-face-meeting, step 2

Table 5 Definition of recommended outcome-domains and results of voting from round 3 online survey (step 2, 2.3)

Table 1 initial outcome-domains derived from systematic literature review and panel suggestion with voting results from round 2 of online survey (step 1, 1.2)

Online survey 1.2 (N=22)			-daily record keeping- [1-9]			-Efficacy/effectiveness studies- [1-9]		
Core area			Md	min	max	Md	min	max
Derived from Systematic review (step 1)	General quality of life		4,5	1	9	7	3	9
	Health related quality of life		7	1	9	8	7	9
	Sickness impact		4,5	1	9	7	3	9
	Mental health		4	1	8	7	3	9
	Physical health		4,5	1	8	7	3	9
	Social health		4,5	1	8	7	3	9
Domain			Md	min	max	Md	min	max
Derived from Systematic review (step 1)	Physical Health*	Disability in general	4	1	9	7	2	9
		Pain-related disability	7,5	1	9	8,5	3	9
		Functional/physical disability	6,5	1	9	7	3	9
		Pain as a symptom	7	1	9	8	1	9
		Pain intensity/severity	9	3	9	9	5	9
		Pain site	5,5	1	9	7	2	9
		Physical function	7	1	9	7,5	5	9
	Mental Health*	Psychological/emotional distress/strain	7,5	1	9	8,5	3	9
		Depressive symptom	7	1	9	7	3	9
		General fear	4	1	7	5	2	8
		Fear of pain	7	1	9	7	3	8
		Avoidance of movement	7,5	1	9	8	3	9
		General coping	5	1	8	6	3	9
		Pain-related coping	7	1	8	7	3	9
		Pain-related catastrophizing	6	1	9	7	3	9
		General self-efficacy	4	1	8	6	3	9
		Pain-related self-efficacy	6	1	9	8	3	9
	Social Health*	Work ability	7	1	9	7	5	9
		Return to work	5	1	9	8	5	9
		Sick leave	5	1	9	7	5	9
		Actual work status	3,5	1	7	6,5	1	9
Derived from panel by suggestion in step 1, 1.2	unassigned	Patient's individual treatment goals	6	1	8	7	1	9
		Ability to do unpaid work activity	4,5	1	9	6	2	9
		Fatigue due to pain	7	1	9	7	2	9
		Difficulty concentrating due to pain	6	1	9	7	2	9
		Maintain relationships/maintain relationships in the presence of pain	6	1	9	7	5	9
		Confidence to live with pain	5	1	8	6,5	1	8
		Analgesic medication/taken taken analgesics	7	3	9	6	4	9
		Reasons for dropout or withdrawal from treatment	6	1	9	7	1	9
		Daily physical activity	7	1	9	6,5	1	9
		Patients global impression of change	5,5	1	9	7	4	8
		Pain frequency, i.e. attacks in migraine	7	1	9	7	3	9
		Pain diary and medication for at least 4 continuous days	6	1	9	6	1	8
		Body awareness	5	1	8	6	1	9
		Autonom function	5	1	9	5	1	9
		Quality of relationships and engagement in social activities	6	1	9	7	3	9
		Engagement in leisure activities	6,5	2	9	7	3	8
		Use of health care services	7	1	9	7	5	9
		Activities to compensate pain	6,5	1	9	6	1	8
		Personal goal achievement	7	1	9	7	1	9
	* referring to PROMIS systematic of self-reported Health outcome areas and domains ²⁹ to ensure bio-psycho-social complexity Md Median, min Minimum, max Maximum, ES effectiveness studies, DRK daily record keeping							

Table 2 Participants and Organizations

	Name of organization/scientific association	n
Physicians	German Pain Society (Chapter of International Association for the Study of Pain)	2
	German Migraine- and Headache Society (DMKG)	1
	European Pain Federation (EFIC)	2
Physiotherapists	Chartered Society of Physiotherapy (C.S.P.)	1
	German Federation of Physiotherapy (ZVK)	1
	AXXON, Physical Therapy in Belgium	1
	Swedish Association of Physiotherapists	1
	Koninklijk Nederlands Genootschap Voor Fysiotherapie (K.N.G.F.)	1
Psychotherapists	German Association for Psychological Pain Therapy and Research (DGPSF)	2
	European Pain Federation (EFIC)	1
	International Association for the Study of Pain (IASP)	2
Researchers	Harmonizing Outcome Measures for Eczema (HOME)	2
	Core outcome measures in effectiveness trials (COMET)	1
	Outcome Measures in Rheumatology (OMERACT)	1
	Consensus-based standards for the selection of health measurement instruments (COSMIN)	1
Patient representatives	German pain league	1
	Patient federation "SchmerzLOS e.V."	1
	German headache league	1
	Pelvic Pain support network	1
	nominated by survey participants	1

ACCEPTED

Table 3 Sample size description of participants

Age (years)	Mean		Range
	48		29 – 70
Gender	Gender		Number (Percent of participants)
	Female		11 (44 %)
	Male		14 (56 %)
Country	Name		Number (Percent of participants)
	Germany		11 (44 %)
	United Kingdom		4 (16 %)
	Netherlands		3 (12 %)
	Belgium		2 (8 %)
	Italy		2 (8 %)
	Canada		1 (4 %)
	Sweden		1 (4 %)
	United States of America		1 (4 %)
Experience*	N	Mean (years)	Range (years)
Professional Experience	20	19	5 - 45
Professional Experience in Current Role	19**	17	2 - 45
* no patients; ** n=19; one missing answer			

Table 4 final voting on outcome-domains for IMPT, face-to-face-meeting, step 2

	%			N
	Yes	No	Abstention	
Pain Intensity	87	13	0	23
Emotional Wellbeing	83	9	8	23
Health related Quality of Life	82	18	0	22
Satisfaction with Social Roles and Activities	81	19	0	21
Productivity (at home and at work, paid/unpaid work) including the terms presentism and absenteeism	81	14	5	21
Pain Frequency	78	22	0	23
Patient's Perception of Treatment Goal Achievement	78	17	5	23
Physical Activity	73	27	0	22
Reasons for Withdrawal/Dropout*	68	32	0	22
* not voted into COS ES but strongly recommended for enhanced report quality				

Table 5 Definition of recommended outcome-domains and results of voting from round 3 online survey (step 2, 2.3)

Definition of recommended outcome-domains		Final voting (2.3; N=25, 100 %)		
		Agree [%]	Disagree [%]	Abstent. [%]
Pain intensity is defined as how much a patient hurts, reflecting the overall magnitude of the pain experience ¹¹		100	0	0
Pain frequency is defined as the rate of pain episodes relative to a specified time frame. It can be described by duration, frequency and intensity of attacks of (increased) pain. It might occur on top of background pain or in between pain-free periods [no citable reference available]		68	32	0
Physical activity is defined as any bodily movement produced by skeletal muscles that requires energy expenditure – including activities undertaken while working, playing, carrying out household chores, travelling, & engaging in recreational pursuits ⁴²		100	0	0
Emotional well-being is defined as feeling a preponderance of pleasant rather than unpleasant affect in one's life over time ⁹		88	8	4
Health related quality of life is the functional effect of a medical condition and/or its consequent therapy upon a patient. It is thus subjective and multidimensional, encompassing physical & occupational function, psychological state, social interaction & somatic sensation ^{4,34}		80	16	4
Satisfaction with social roles and social activities describes the impact on patient's satisfaction in performing usual social roles and activities (including family and work) ²⁹		84	16	0
Productivity is defined by the output per unit of input, for example production output per labor hours. It comprises paid and unpaid work as well as home work (e.g., housekeeping, caring for infants or sick relatives) ¹		88	4	8
Sub-domains of Productivity	Absenteeism is defined by days off work comprising paid/unpaid work as well as home work (e.g., housekeeping, caring for infants or sick relatives) ¹	100	0	0
	Presentism is defined by having difficulties/inefficiencies at work, where work is paid/unpaid work, or home work (e.g., housekeeping, caring for infants or sick relatives) ¹	96	4	0
Patient's perception of treatment goal achievement: The own perception of the patient regarding the efficacy of the therapy to achieve the predefined treatment goals [no citable definition available]		96	4	0

*EWB emotional wellbeing; **PPoTGA patient perception of treatment goal achievement

IMPT interdisciplinary multimodal pain therapy; COS core outcome set; ES effectiveness studies; DRK daily record keeping